James D. Hays
#172,660
Most Influential Person Now
American climatologist
James D. Hays's AcademicInfluence.com Rankings
James D. Haysearth-sciences Degrees
Earth Sciences
#2849
World Rank
#3827
Historical Rank
#621
USA Rank
Atmospheric Sciences
#251
World Rank
#262
Historical Rank
#54
USA Rank
Download Badge
Earth Sciences
James D. Hays's Degrees
- Bachelors Atmospheric Science University of California, Berkeley
- Masters Climatology Stanford University
Why Is James D. Hays Influential?
(Suggest an Edit or Addition)According to Wikipedia, James D. Hays is a professor of Earth and environmental sciences at Columbia University's Lamont–Doherty Earth Observatory. Hays founded and led the CLIMAP project, which collected sea floor sediment data to study surface sea temperatures and paleoclimatological conditions 18,000 years ago.
James D. Hays's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers (2017) (211)
- Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. (2014) (171)
- Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target (2017) (90)
- Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398 (2017) (70)
- Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma (2020) (65)
- Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (58)
- Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions (2013) (54)
- The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies (2013) (53)
- A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer. (2019) (53)
- Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity (2016) (46)
- Olaparib in the management of ovarian cancer (2015) (46)
- BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma. (2019) (41)
- Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry (2016) (36)
- Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions. (2018) (35)
- Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease (2016) (33)
- Feasibility and safety of sequential research‐related tumor core biopsies in clinical trials (2013) (28)
- A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety. (2013) (26)
- Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. (2019) (21)
- Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 (2016) (20)
- Proteomics and ovarian cancer: integrating proteomics information into clinical care. (2010) (20)
- Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review (2020) (20)
- The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources (2018) (20)
- Oligomerization-induced Modulation of TPR-MET Tyrosine Kinase Activity* (2003) (19)
- CD4 T cell dependent rejection of beta 2 microglobulin null mismatch repair deficient tumors. (2021) (19)
- PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials. (2016) (19)
- The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. (2018) (18)
- Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy. (2008) (18)
- Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer (2017) (18)
- Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation. (2008) (17)
- Outpatient desensitization in selected patients with platinum hypersensitivity reactions. (2017) (16)
- Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. (2017) (15)
- RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer. (2021) (15)
- Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk (2019) (13)
- Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. (2020) (13)
- Impact of Synchronous Liver Resection on the Perioperative Outcomes of Patients Undergoing CRS-HIPEC (2018) (13)
- Mixed adenoneuroendocrine carcinoma: A review of pathologic characteristics. (2017) (12)
- Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma (2019) (11)
- Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma (2019) (11)
- Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges (2022) (10)
- Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research (2020) (10)
- Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma (2019) (9)
- Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis. (2019) (9)
- Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target (2021) (8)
- Outcomes of neoadjuvant chemotherapy before CRS‐HIPEC for patients with appendiceal cancer (2020) (8)
- Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors (2020) (7)
- Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062). (2013) (7)
- Oligomerization-dependent changes in the thermodynamic properties of the TPR-MET receptor tyrosine kinase. (2004) (7)
- A phase II study of intermittent sorafenib with bevacizumab (B) in B-naive and prior B-exposed epithelial ovarian cancer (EOC) patients. (2014) (6)
- MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models (2020) (6)
- Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. (2021) (5)
- A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (2020) (5)
- A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer. (2017) (5)
- Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series (2017) (4)
- Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series (2016) (4)
- Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways (2018) (4)
- A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer. (2016) (4)
- The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies (2020) (4)
- A pilot study of Bruton’s tyrosine kinase inhibitor ibrutinib alone and in combination with PD-1 inhibitor nivolumab in patients with metastatic solid tumors. (2020) (4)
- A pharmacokinetics/pharmacodynamics study of sequence specificity of the PARP inhibitor olaparib with carboplatin in refractory/recurrent women's cancers: NCT01237067. (2011) (4)
- Investigating intra-tumor microbes, blood microbes, and CEA for development of non-invasive biomarkers in colorectal cancer. (2021) (3)
- Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC). (2018) (3)
- Sequence specific effects on DNA and cell damage with the PARP inhibitor olaparib (AZD2281) and carboplatin. (2011) (3)
- A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors. (2016) (3)
- A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab. (2020) (3)
- Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors. (2019) (3)
- Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake (2022) (3)
- Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. (2021) (3)
- Identification of histone deacetylase 2 (HDAC2) as a novel target for MDM2 directed therapies in dedifferentiated liposarcoma. (2018) (2)
- Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer (2021) (2)
- Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas (2022) (2)
- ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. (2022) (2)
- 818TiP Balstilimab alone or in combination with zalifrelimab as second-line treatment for patients with previously treated recurrent/metastatic cervical cancer (R/M CC): A randomized, placebo-controlled phase II trial (RaPiDS/GOG-3028) (2021) (1)
- ATNT-18A PHASE I STUDY OF MLN0128 AND BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND OTHER SOLID TUMORS (2015) (1)
- Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer (2019) (1)
- Practice patterns in post-treatment surveillance in patients with primary epithelial ovarian cancer (2020) (1)
- Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076) (2022) (1)
- Irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): A single institution experience. (2016) (1)
- Abstract 1188: BRCA 1/2 mutation status is correlated with increased hypersensitivity reactions to carboplatin. (2013) (1)
- Loss of TXNIP enhances peritoneal metastasis and can be abrogated by dual TORC1/2 inhibition (2018) (1)
- Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers (2015) (1)
- Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT+) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062) (2013) (1)
- 852 - Safety of Synchronous Liver Resecection with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An ACS-NSQUIP Analysis (2018) (0)
- A phase II study of PD-1 inhibition for the prevention of colon adenomas in patients with Lynch syndrome and a history of partial colectomy. (2019) (0)
- Abstract 1754: A pharmacokinetics/pharmacodynamics study of sequence specificity of the PARP inhibitor, olaparib (O) with carboplatin (C) in recurrent women's cancers NCT01237067 (2012) (0)
- TP024/#446 Upgrade: phase 1 combination trial of the NAPI2B-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UPRI; XMT-1536) in patients with ovarian cancer (2022) (0)
- Determinants of secondary alterations in WWTR1-CAMTA1 fusion epithelioid hemangioendothelioma. (2019) (0)
- Association of liver-directed local therapy with overall survival in metastatic intrahepatic cholangiocarcinoma. (2019) (0)
- Abstract LB-28: Suppression of ovarian tumor growth and metastasis with a STAT3 inhibitor, HO-3867, in preclinical orthotopic models and ex vivo cultures of ovarian cancer (2014) (0)
- Phase 1 study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors. (2017) (0)
- Association of breast cancer risk in BRCA 1 and BRCA 2 mutation carriers with genetic variants showing differential allelic expression (2016) (0)
- Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer. (2021) (0)
- 839P A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer (2020) (0)
- 33 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer (2022) (0)
- Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies. (2012) (0)
- Biologically optimized schedule of gemcitabine and nab-paclitaxel regimen in metastatic pancreatic adenocarcinoma. (2021) (0)
- Multiscale omic assessment of EWSR1-NFATc2 fusion positive sarcomas to identify conserved fusion breakpoint and activation of the mTOR pathway. (2020) (0)
- Abstract 828: Progranulin is a good predictive biomarker in ovarian cancer patients followed in first remission (2010) (0)
- Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) - Phase 2 Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations: Sub-protocol EAY131-M (2022) (0)
- Genomic profiling of young adults with colorectal cancer: A single-institution experience. (2017) (0)
- An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer. (2020) (0)
- ACTR-93. A PHASE I STUDY OF MLN0128 (TAK-228) AND BEVACIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING GLIOBLASTOMA (2017) (0)
- Prevalence, symptom management, and reporting of cannabis use among invasive cancer patients. (2022) (0)
- UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in platinum-resistant ovarian cancer (585) (2022) (0)
- Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer (588) (2022) (0)
- Oligomerization-induced Modulation of TPR-MET Tyrosine (2003) (0)
- Abstract C124: Proteomic and phenotype derived model for selection of combinations of targeted therapies in ovarian cancer. (2013) (0)
- 32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer (2022) (0)
- 2022-RA-687-ESGO ARTISTRY-7: phase 3, multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68) (2022) (0)
- The Role of Anti-angiogenic Therapy in the Management of Gynecologic Malignancies: A Review (2015) (0)
- Genomic alterations in the homologous recombination pathway in soft-tissue sarcomas. (2018) (0)
- TP036/#426 Uplift (ENGOT-OV67/GOG-3048) a pivotal cohort of the XMT-1536–1 trial of upifitamab rilsodotin (XMT-1536; UPRI), a NAPI2B-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer (2022) (0)
- The siren's song of anonymous web‐based sampling (2022) (0)
- Timely delivery of primary chemoradiation for the treatment of locally advanced cervical cancer: are we meeting this quality measure? (2017) (0)
- Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (2022) (0)
- Suppression of ovarian cancer growth and metastasis with HO-3867, a STAT3 inhibitor, in human tissue culture and in an orthotopic mouse model (2015) (0)
- Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (2022) (0)
- CEACAM6 as a candidate biomarker for pelareorep sensitivity in pancreatic adenocarcinoma (PDAC). (2020) (0)
- Abstract 3475: Progranulin as a prognostic biomarker of advanced epithelial ovarian cancer. (2013) (0)
- Abstract 3529: Modulation of MDM2 alters the metabolomic programming of dedifferentiated liposarcoma and its sensitivity to cholesterol inhibition (2018) (0)
- Genomic amplification of CDK4 in dedifferentiated liposarcomas as a predictive biomarker for microtubule disrupting agents. (2018) (0)
- Abstract 35: Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors (NCT01445509). (2013) (0)
- Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (0)
- Increased phosphorylation of RB and protein expression of Cyclin E confers resistance to CDK4/6 inhibitors in dedifferentiated liposarcoma. (2022) (0)
- 728P A phase Ib/II study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer (2020) (0)
- Histone H3 modifying genes may serve as a predictive marker for metastasis in synovial sarcoma. (2019) (0)
- EP017/#425 Comparison of NAPI2B expression from paired tissue samples in a clinical study of upifitamab rilsodotin (UPRI; XMT-1536) supports a strategy of testing in archive material (2022) (0)
- ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (326) (2022) (0)
- Abstract 335: Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma (2019) (0)
- 564 Safety and clinical activities of the acid pH-sensitive anti-CTLA-4 mAb ONC-392 in ovarian cancer patients (2022) (0)
- Exploring ceramide metabolism as a potential target in dedifferentiated liposarcoma. (2019) (0)
- TP025/#1399 Artistry-7: phase 3 multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (2022) (0)
- Abstract 2777: Characterizing the molecular underpinnings of sorafenib sensitivity in desmoid tumors (2022) (0)
- Supplemental B-Vitamins and Risk of Upper Gastrointestinal Cancers in the Women’s Health Initiative (2023) (0)
- OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer (2021) (0)
- Abstract LB-036: Elevated STAT3 expression in ovarian tumor ascites regulates invasion and metastasis: a promising therapeutic target (2016) (0)
This paper list is powered by the following services:
Other Resources About James D. Hays
What Schools Are Affiliated With James D. Hays?
James D. Hays is affiliated with the following schools:
